Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)

Exclusion Criteria

• •Women who are pregnant, nursing or planning pregnancy
• •Unwillingness to submit a blood pregnancy test at screening and the last visit (or early termination visit) if of childbearing potential, or unwillingness to use acceptable means of birth control
• •Clinically significant slit-lamp findings or abnormal lid anatomy at screening and Visit 1
• •Ocular/peri-ocular malignancy
• •History of herpetic keratitis
• •Active ocular allergies or ocular allergies that are expected to be active during the study
• •Ongoing ocular or systemic infection
• •Wear contact lenses within 1 month prior to screening or anticipated use of contact lenses during the study
• •Intra-ocular surgery or ocular laser surgery within the previous 6 months, or have planned ocular and/or lid surgeries over the study period
• •Presence of uncontrolled systemic diseases
• •Presence of known allergy and/or sensitivity to the study drug or saline components
• •Use of any topical steroids treatments, topical cyclosporine, lifitegrast, serum tears or topical anti-glaucoma medication within 2 months prior to screening